CAI (CAI) Stock Forecast & Price Target

Caris Life Sciences is positioned for attractive fundamental upside because its core molecular profiling business is compounding on the back of strong clinical demand, with Q2 revenue of $264M up 45% Y/Y, adjusted EBITDA of $56M, and healthy operating cash flow alongside $793M of cash. Its sales force reorganization appears to be working, with therapy selection volumes up 12% q/q to 59.2k, territories expanded from 82 to 146, and the company expecting about 20% clinical volume growth in 2026 while remaining EBITDA and FCF positive. The investment case is further strengthened by premium reimbursement for MI Cancer Seek at $8,455 per test, broad payer and physician adoption, and pipeline catalysts such as Caris Detect, Chromoseq, and MRD tests that could add incremental upside to already profitable growth.

Caris Life Sciences is facing a negative outlook because slower-than-expected revenue contribution from Caris Assure and softer-than-expected volume growth signal commercialization risk in newer blood-based testing, even after +85% Y/Y core revenue growth and a Q1 top- and bottom-line beat. It also faces intense competition from large, established laboratory companies across tissue, blood, MRD, and early detection markets, alongside valuation volatility in precision oncology and a balance sheet that may require additional capital. In addition, the early Detect launch is priced at $3,500 per test, lacks reimbursement and FDA clearance, and relies on a relatively small study of just above 3,000 participants, leaving meaningful development and legal risks.